Zoetis (NYSE:ZTS) Rating Lowered to “Neutral” at Piper Sandler

Zoetis (NYSE:ZTS) was downgraded by equities researchers at Piper Sandler from an “overweight” rating to a “neutral” rating in a report released on Thursday, Marketbeat Ratings reports. They presently have a $135.00 price target on the stock. Piper Sandler’s target price would suggest a potential upside of 8.56% from the stock’s current price.

A number of other research analysts have also weighed in on the stock. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. UBS Group decreased their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 13th. Barclays assumed coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Finally, Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target on the stock. in a research report on Monday, December 15th. Five equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Price Performance

Shares of ZTS stock opened at $124.35 on Thursday. The company has a market capitalization of $54.80 billion, a P/E ratio of 20.93, a P/E/G ratio of 2.17 and a beta of 0.97. The stock has a 50 day moving average of $123.51 and a two-hundred day moving average of $138.66. Zoetis has a 12 month low of $115.25 and a 12 month high of $177.40. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis will post 6.07 EPS for the current year.

Hedge Funds Weigh In On Zoetis

Institutional investors and hedge funds have recently bought and sold shares of the company. Halbert Hargrove Global Advisors LLC grew its holdings in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. Global Wealth Strategies & Associates acquired a new stake in Zoetis during the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis during the 4th quarter worth approximately $30,000. REAP Financial Group LLC increased its position in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the period. Finally, KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis during the third quarter valued at $31,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.